Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: A phase 3, randomised, double-blind, non-inferiority trial

The Lancet Neurology

Volumn 11, Issue 7, 2012, Pages 579-588

  Baulac, Michel ^a   Brodie, Martin J ^b   Patten, Anna ^c   Segieth, Joanna ^c   Giorgi, Luigi ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b WESTERN INFIRMARY   (United Kingdom)

^c EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CARBAMAZEPINE; ZONISAMIDE;

ADULT; ARTICLE; BICARBONATE BLOOD LEVEL; CONTROLLED STUDY; DECREASED APPETITE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOCAL EPILEPSY; FOLLOW UP; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; METABOLIC ACIDOSIS; MONOTHERAPY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREATMENT WITHDRAWAL; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CARBAMAZEPINE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EPILEPSIES, PARTIAL; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862311867     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70105-9     Document Type: Article

References (38)

1. Kwan P, Brodie MJ Early identification of refractory epilepsy. N Engl J Med 2000, 342:314-319.
2. Kwan P, Brodie MJ Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology 2003, 60(suppl 4):S2-12.
3. Porter RJ, Baulac M, Nohria V Clinical development of drugs for epilepsy: a review of approaches in the United States and Europe. Epilepsy Res 2010, 89:163-175.
4. Biton V Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 2007, 30:230-240.
5. Zonegran Summary of Product Characteristics, (accessed Feb 8, 2012). http://www.medicines.org.uk/emc/medicine/16240/SPC/Zonegran%20capsules.
6. Zonegran Prescribing Information, (accessed Feb 8, 2012). http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020789s022s025lbl.pdf.
7. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993, 15:67-73.
8. Faught E, Ayala R, Montouris GG, Leppik IE Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001, 57:1774-1779. Zonisamide 922 Trial Group.
9. Sackellares JC, Ramsay RE, Wilder BJ, Browne TR, Shellenberger MK Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004, 45:610-617.
10. Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005, 46:31-41.
11. Wroe SJ, Yeates AB, Marshall A Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy. Acta Neurol Scand 2008, 118:87-93.
12. Ohtahara S Zonisamide in the management of epilepsy: Japanese experience. Epilepsy Res 2006, 68(suppl 2):S25-S33.
13. Dupont S, Striano S, Trinka E, et al. Flexible dosing of adjunctive zonisamide in the treatment of adult partial-onset seizures: a non-comparative, open-label study (ZEUS). Acta Neurol Scand 2010, 121:141-148.
14. Stephen LJ, Kelly K, Wilson EA, Parker P, Brodie MJ A prospective audit of adjunctive zonisamide in an everyday clinical setting. Epilepsy Behav 2010, 17:455-460.
15. Schulze-Bonhage A Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother 2010, 11:115-126.
16. Catarino CB, Bartolini E, Bell GS, Yuen AW, Duncan JS, Sander JW The long-term retention of zonisamide in a large cohort of people with epilepsy at a tertiary referral centre. Epilepsy Res 2011, 96:39-44.
17. CHMP Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders 2009, European Medicines Agency Committee for Proprietary Medicinal Products (CPMP), CHMP, London, (accessed Feb 8, 2012). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003531.pdf.
18. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006, 47:1094-1120.
19. Koch GG, Carr GJ, Amara IA, et al. Categorical data analysis. Statistical methodology in pharmaceutical sciences 1990, 391-475. Marcel Dekker, New York. D.A. Berry (Ed.).
20. Brown EG, Wood L, Wood S The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999, 20:109-117.
21. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007, 68:402-408. Levetiracetam Monotherapy Study Group.
22. Kwan P, Brodie MJ, Kälviäinen R, Yurkewicz L, Weaver J, Knapp LE Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol 2011, 10:881-890.
23. Marson AG, Williamson PR Interpreting regulatory trials in epilepsy. Curr Opin Neurol 2009, 22:167-173.
24. French J What is a fair comparison in head-to-head trials of antiepileptic drugs?. Lancet Neurol 2011, 10:866-867.
25. King MA, Newton MR, Jackson GD, et al. Epileptology of the first-seizure presentation: a clinical, electroencephalographic, and magnetic resonance imaging study of 300 consecutive patients. Lancet 1998, 352:1007-1011.
26. Perucca E, Gram L, Avanzini G, Dulac O Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998, 39:5-17.
27. Perucca E Designing clinical trials to assess antiepileptic drugs as monotherapy: difficulties and solutions. CNS Drugs 2008, 22:917-938.
28. Naritoku D Dose responsive efficacy of zonisamide monotherapy during 40 weeks treatment of partial seizures in patients with newly diagnosed epilepsy. Epilepsia 2006, 47(suppl 3):138-139.
29. Brodie MJ, Richens A, Yuen AW Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995, 345:476-479.
30. Chadwick D Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet 1999, 354:13-19.
31. Brodie MJ, Wroe SJ, Dean AD, Holdich TA, Whitehead J, Stevens JW Efficacy and safety of remacemide versus carbamazepine in newly diagnosed epilepsy: comparison by sequential analysis. Epilepsy Behav 2002, 3:140-146.
32. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003, 107:165-175. EPMN 105 Study Group.
33. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005, 64:1868-1873. VA Cooperative Study 428 Group.
34. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985, 313:145-151.
35. Mattson RH, Cramer JA, Collins JF A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992, 327:765-771.
36. Aihara M Pharmacogenetics of cutaneous adverse drug reactions. J Dermatol 2011, 38:246-254.
37. Wellmer J, Wellmer S, Bauer J The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy. Acta Neurol Scand 2009, 119:233-238.
38. Griffith SG, Dai Y Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. Clin Ther 2004, 26:2056-2065.